Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bladder cancer drug shows promise in early trial

NCT ID NCT07222488

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-3120 (SKB410), a biologic given directly into the bladder
What this could lead to
If it works, this could offer a new treatment option for people with high-risk bladder cancer that hasn't spread to the muscle.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply broadly. Side effects like bleeding or severe lab abnormalities are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ superficial urinary bladder carcinoma urinary bladder carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER URINARY BLADDER NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Akershus Universitetssykehus ( Site 0091)

    RECRUITING

    Lorenskog, Akershus, 1478, Norway

  • Ankara University Health Practice and Research Hospitals ( Site 0132)

    RECRUITING

    Ankara, 06620, Turkey (Türkiye)

  • CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)

    RECRUITING

    Québec, Quebec, G1J 1Z4, Canada

  • Carolina Urologic Research Center ( Site 0006)

    RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • Centro Ricerche Cliniche di Verona ( Site 0072)

    RECRUITING

    Verona, Veneto, 37134, Italy

  • European Interbalkan Medical Center ( Site 0051)

    RECRUITING

    Thessaloniki, 570 01, Greece

  • Gustave Roussy ( Site 0041)

    RECRUITING

    Villejuif, Val-de-Marne, 94805, France

  • Hospital Universitario 12 de Octubre ( Site 0112)

    RECRUITING

    Madrid, Madrid, Comunidad de, 28041, Spain

  • Hospital Universitario Virgen de la Victoria ( Site 0111)

    RECRUITING

    Málaga, Andalusia, 29010, Spain

  • Koc Universitesi Hastanesi ( Site 0133)

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • Medizinische Universität Wien ( Site 0021)

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

  • Michael G Oefelein Clinical Trials ( Site 0005)

    RECRUITING

    Bakersfield, California, 93301, United States

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Rabin Medical Center ( Site 0062)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • UZ Gent ( Site 0031)

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.